Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Oncology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Oncology Other
    ATA Publishes Revised Guidelines for Managing Thyroid Cancer - (DGNews)
    Brain Tumours In Childhood Leave a Lasting Mark On Cognition, Life Status - (DGNews)
    Patients With Diverticulosis May Require Less Aggressive Screening for Colonic Polyps: Presented at ACG - (DGDispatch)
    High Definition Colonoscopy Increases Polyp Detection: Presented at ACG - (DGDispatch)
    Ascorbic Acid-Based Prep Improves Bowel Cleansing, Increases Small Adenoma Detection Rate During Colonoscopy: Presented at ACG - (DGDispatch)

    News archive

     Recent webcasts/CME - Oncology Other
    • Questioning Clinical Assumptions in Accelerated-Phase and Blast-Crisis CML
    • Carcinoid Tumors of the Gastrointestinal Tract
      Cancer, Liver, Infections, Cardiovascular Disease, and other Biologic Agents
      Multidisciplinary Approach to Management of Neuroendocrine Tumors
      Cancer and Venous Thromboembolism: Current Clinical Issues

      Webcasts/CME archive

       Recent cases - Oncology Other
        Giant Thoracic Schwannoma Presenting with Abrupt Onset of Abdominal Pain: A Case Report
        Novel Deployment of a Covered Duodenal Stent in Open Surgery to Facilitate Closure of a Malignant Duodenal Perforation
        Clinical Experience of Novel Interconnected Porous Hydroxyapatite Ceramics for the Revision of Tumor Prosthesis: A Case Report
        Superior Vena Cava (SVC) Reconstruction Using Autologous Tissue in Two Cases of Differentiated Thyroid Carcinoma Presenting with SVC Syndrome
        Surgical Treatment of a Giant Tibial High-Grade Mixofibrosarcoma with Preservation of Limb Function: A Case Report

        Cases archive
          




        my personal edition > oncology other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Primary Tumour Histology Important in Determining Brain Metastasis Survival

        A DGReview of :"Prognostic Factors for Patients with Microsurgically Resected Brain Metastases"
        Onkologie

        11/19/2002
        By Elda Hauschildt


        Histology of the primary tumour is one of the most important factors in determining survival times in patients after microsurgical resection for brain metastases.

        Preoperative Kamofsky scale score, location of the metastasis and preoperative symptom duration are also important, German researchers report.

        "Microsurgical resection of one or more brain metastases followed by whole-brain radiation therapy (WBRT) is still a useful and efficient treatment in a carefully selected patient group to prolong survival and improve or stabilise performance status," concluded the investigators from the Universitatsklinikum der RWTH Aachen in Aachen.

        The retrospective review included data on 187 consecutive patients: 85 with lung cancer; 20 with gastrointestinal cancer, 19 with renal cell cancer, 17 with breast cancer, 8 with malignant melanoma and 38 others with various carcinomas or with unknown primary sites.

        Participants underwent microsurgical resection of brain metastases between July 1989 and September 1996. After tumour resection, 111 patients underwent WBRT, with a mean dose of 32 Gy.

        The researchers evaluated eight prognostic factors. These included the influence of the number, size and localisation of brain metastases as well as primary tumour histology, preoperative performance status, presence of extra-cranial system disease, time course and adjuvant radiation therapy.

        Early postoperative Kamofsky score improved in 59 percent of patients. It remained unchanged in 32 percent and was worse in 9 percent.

        The investigators say the median survival time was 9.8 months, with a range of 1 day to 5.3 years.

        Histology of the primary tumour significantly influenced survival time, predicting a negative outcome especially for patients with metastases from renal cell cancers and malignant melanomas. Breast cancer patients survived longer than other patients.

        "Survival varied significantly depending on location of the brain metastases, performance status at the time of craniotomy and duration of symptoms," the researchers note.
        Onkologie, 2002; 25: 420-425. "Prognostic Factors for Patients with Microsurgically Resected Brain Metastases"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send